Wakame

Other Names

Alaria amplexicaulis MartensAlaria pinnatifida HarveyApron-ribbon vegetableAsian kelpFougère des mersGwymon wacameHaijiecaiHirome undarioides YendoJapanese kelpLaminaria peterseniana KjellmanMekabuMiyeokMiyeukQundaicaiQúndàicàiSea mustardUlopteryx pinnatifida (Harvey) KjellmanUndaria peterseniana (Kjellmann) OkamuraUndaria pinnatifida (Harvey) SuringarUndaria pinnatifida f. distans (Miyabe & Okamura) YendoUndaria pinnatifida f. narutensis YendoUndaria pinnatifida f. subflabellata SuringarUndaria pinnatifida f. typica YendoUndaria pinnatifida var. distans Miyabe & OkamuraUndaria pinnatifida var. elongata SuringarUndaria pinnatifida var. vulgaris SuringarUndaria undarioides (Yendo) OkamuraUndariella peterseniana (Kjellman) Y.-P.LeeUndariopsis peterseniana (Kjellmann) Miyabe & OkamuraWakaméワカメ和布若布裙带菜미역

Synopsis

Wakame (Undaria pinnatifida): A Comprehensive Reference

1. Identity and Taxonomy

Scientific Classification and Common Names

Wakame (Undaria pinnatifida) is a species of kelp native to cold, temperate coasts of the northwest Pacific Ocean. It belongs to the family Alariaceae. Its primary common names vary by language and culture: miyeuk in Korean, wakame in Japanese, and qundaicai or haijiecai in Chinese; English-language common names include Japanese kelp, Asian kelp, and apron-ribbon vegetable.

Wakame, as with all other kelps and brown algae, is plant-like in appearance but is unrelated to true plants, being instead a photosynthetic, multicellular stramenopile protist of the SAR supergroup. It is therefore more precisely classified as a brown macroalga (phylum Ochrophyta) rather than a plant, though in practical, nutritional, and regulatory contexts it is routinely referred to as a seaweed or sea vegetable.

Morphology and Habitat

Wakame is a brown seaweed kelp that grows to 1–3 metres in height. Plants are a golden-brown colour and consist of a holdfast, cylindrical stipe (stem), and a flattened, branched blade, with the stipe extending as a mid-rib through the blade. When alive, the frond is reddish-brown; upon boiling it turns bright green. It is an annual species with two separate life stages: a macroscopic stage (the sporophyte), usually present through the late winter to early summer months, and a microscopic stage (the gametophyte), present during the colder months.

Although native to cold, temperate coastal areas of Japan, Korea, China, and Russia, it has established itself in temperate regions around the world, including New Zealand, the United States, Belgium, France, Great Britain, Spain, Italy, Argentina, Australia, and Mexico. As of 2018, the Invasive Species Specialist Group has listed the species on its list of 100 worst globally invasive species.

The Mekabu Sporophyll

The part most commonly consumed — the blade (the "leaves" of the seaweed) — contains bioactive compounds, but not as much as the mekabu. The mekabu is the reproductive part of the wakame, located at the base of the alga, where it clings to the substrate. This part, which resembles a kind of ruffle or undulation, is particularly rich in bioactive compounds. Analyses show that the concentration of fucoidan in mekabu can be up to ten times higher than in the blade. In Japan, mekabu is consumed separately and is highly valued for its properties, representing a market worth several hundred million euros annually.

Common Forms and Preparations

Wakame is marketed and consumed in several forms:

Fresh / salted: Traditionally, wakame was harvested from the wild and used in various dishes, particularly soups and salads.
Dried: Dried wakame has a concentrated flavour, needs to be rehydrated before use, is ideal for soups, stews, and salads, and has a long shelf life.
Pickled: Pickled wakame is marinated in vinegar and spices, giving it a tangy flavour; it is served as a side dish or salad, often found in Korean cuisine.
Powder: Wakame powder is made by drying and grinding wakame into a fine powder and can be added to smoothies, sauces, and dressings.
Encapsulated extracts: Undaria pinnatifida is a rich source of fucoxanthin and is widely used as a human food in many countries, becoming increasingly popular in the European market above all in the form of extracts used as food supplements. Standardised extracts of fucoidan and fucoxanthin are also sold as standalone supplements.

2. Traditional and Historical Use

Japan

Wakame has long been collected for food in East Asia, and sea farmers in Japan have cultivated wakame since the eighth century (Nara period). Remnants of seaweeds, including wakame, have been found in remains from the Jōmon period, indicating its consumption is ancient. The history of wakame is deeply rooted in East Asian culinary traditions, particularly in Japan, where it has been consumed for over a thousand years. Historical records suggest that wakame was once considered a valuable food reserved for nobility and religious offerings. Over time, it became more widely available and evolved into an everyday ingredient used in households across coastal regions.

In Oriental medicine it has been used for blood purification, intestinal strength, skin, hair, reproductive organs, and menstrual regularity. It was believed to support blood purification, improve skin health, and aid in digestion. In some traditional practices, wakame was used as a remedy for goiter, due to its high iodine content.

Korea

In Korea, wakame was already consumed during the Three Kingdoms period (until the 7th century), and the tradition of eating wakame soup for birthdays is still alive today. In Korea, miyeok-guk soup is popularly consumed by women after giving birth, as sea mustard (miyeok) contains a high content of calcium and iodine — nutrients that are important for new nursing mothers. Many women consume it during the pregnancy phase as well. It is also traditionally eaten on birthdays as a reminder of the first food that the mother has eaten and passed on to her newborn through her milk.

Broader East Asian Traditions

For centuries, traditional Japanese, Korean, and Chinese medicine have valued wakame for its health-promoting properties. Ancient texts and folk remedies document its application in supporting cardiovascular health, alleviating digestive issues, and promoting general vitality. These traditional usages predated and motivated much of the modern scientific investigation into wakame's bioactive constituents.

Aquaculture and Spread

Japanese and Korean sea farmers have cultivated wakame for centuries and remain the main producers and consumers. The seaweed is also cultivated in France since 1983. This brown seaweed was introduced to France in 1971, probably on imported Pacific oysters, and was later deliberately imported into France, where it is still cultivated as a food plant.

3. Nutritional Composition

Wakame seaweed, like most algae, is rich in minerals such as calcium, sodium, potassium, iron, magnesium, and iodine; vitamins including vitamin B₁₂, A, C, and E; fibres; and high-value proteins. Wakame also contains unique compounds including fucoxanthin, fucoidan, and alginic acid, along with high concentrations of iodine, vitamin K, folate, and omega-3 fatty acids.

The protein content of dried wakame has been reported at approximately 16.8%, fat content at approximately 1%, carbohydrates at 37%, fibre content at 16.9%, and ash (mineral) content at 28.3%. Both wakame and the red seaweed nori contain high concentrations of calcium, sodium, potassium, iron, and magnesium, with vitamin A being the most abundant vitamin.

Wakame represents an excellent source of phospholipids, including fatty acyl chains featuring a valuable ω-3/ω-6 ratio. It is also characterised by a remarkable content of extra nutritional compounds such as polyphenols, carotenoids, and fucoidans.

Research published in PMC used liquid chromatography–mass spectrometry to characterise the lipidome of wakame in detail. The study focused on phospholipids and glycolipids, characterising more than 200 phospholipid and glycolipid species, including sulfoquinovosyl diacylglycerol (SQDG), digalactosyl diacylglycerol (DGDG), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylethanolamine (PE), and phosphatidylcholine (PC) classes.

4. Key Bioactive Constituents and Mechanisms of Action

4.1 Fucoxanthin

Fucoxanthin (Fx) is a major xanthophyll in Undaria pinnatifida (wakame) and is one of the potent carotenoids investigated in relation to cancer development. It is an orange-coloured carotenoid pigment belonging to the xanthophyll subclass of carotenoids and functions as a light-harvesting and photoprotective molecule in aquatic plants. The compound accounts for more than 10% of all naturally occurring carotenoids on Earth.

Fucoxanthin possesses a number of beneficial medicinal qualities, including anti-oxidant, anti-obesity, and anti-cancer properties. Its anti-obesity mechanism has been traced to thermogenesis: mitochondrial uncoupling protein 1 (UCP1) is usually expressed only in brown adipose tissue (BAT) and is a key molecule for metabolic thermogenesis to avoid excess fat accumulation; however, there is little BAT in adult humans, and therefore UCP1 expression in tissues other than BAT is expected to reduce abdominal fat. Rodent studies showed a reduction of abdominal white adipose tissue (WAT) weights by feeding lipids from Undaria pinnatifida; clear signals of UCP1 protein and mRNA were detected in WAT of mice fed the Undaria lipids, which mainly consisted of glycolipids and the carotenoid fucoxanthin, while fucoxanthin-fed mice showed significantly decreased WAT weight and clear UCP1 expression in WAT.

In the liver, fucoxanthin's metabolites suppress key fat-creating enzymes — fatty acid synthase (FAS), malic enzyme, and glucose-6-phosphate dehydrogenase (G6PDH) — so while existing fat burns faster through UCP1 thermogenesis, new fat synthesis slows down simultaneously. The compound also decreases plasma leptin levels and suppresses inflammatory cytokines (TNF-alpha and IL-6) released from macrophages in enlarged fat tissue.

Fucoxanthin provides protective effects on the liver, blood vessels of the brain, bones, skin, and eyes.

4.2 Fucoidan

Fucoidans are fucose-enriched sulfated polysaccharides isolated from brown algae and marine invertebrates, and have been shown to exert anticancer activity in several types of human cancer, including leukemia, breast cancer, and lung adenocarcinoma cells. Mekabu is especially rich in fucoidan, a naturally occurring polysaccharide found in brown seaweeds; fucoidan has been studied for its potential health benefits, particularly due to its high content of fucose (a type of sugar) and sulfate groups, which give it unique biological properties.

Fucoidan from wakame has demonstrated multiple mechanisms of action in preclinical research: fucoidan from U. pinnatifida has been shown to induce apoptosis in various cancer cells via the ROS-mediated mitochondrial pathway or through down-regulation of p38, PI3K/Akt, and the activation of the ERK1/2 MAPK pathway. It also possesses anticoagulant, immunomodulatory, antiviral, and antiprotozoal biological activities.

Regarding immune effects, this polysaccharide modulates Th2 responses and thus might be useful for treating allergic inflammation, and mediates tumour destruction through responses of Th1 and NK cells.

4.3 Fucosterol

Laboratory evidence shows that carotenoids (fucoxanthin and fucoxanthinol), polysaccharides (fucoidan), and sterols (fucosterol) are the principal bioactive metabolites in wakame. Fucosterol is a marine phytosterol structurally distinct from plant sterols, and has been associated with cholesterol-lowering and anti-inflammatory activity in preclinical models, though robust human clinical data for wakame-derived fucosterol specifically remain limited.

4.4 Bioactive Peptides (ACE-Inhibitory Peptides)

Wakame contains bioactive peptides capable of inhibiting angiotensin-converting enzyme (ACE). Studies have examined the ACE inhibitory activity and antihypertensive effect of hot water extract of wakame, from which ten dipeptides were isolated by chromatography, including Tyr-His, Lys-Trp, Lys-Tyr, Lys-Phe, Phe-Tyr, Val-Trp, Val-Phe, Ile-Tyr, Ile-Trp, and Val-Tyr. Both single and repeated oral administration of synthetic Tyr-His, Lys-Tyr, Phe-Tyr, and Ile-Tyr significantly decreased blood pressure in spontaneously hypertensive rats.

4.5 Alginic Acid / Alginates and Dietary Fibre

Mekabu contains a dense payload of soluble fibres (fucoidan, alginate, laminarin), minerals (notably iodine), and marine polyphenols. Alginates are polysaccharides found in brown seaweeds that act as dietary fibre in the gastrointestinal tract, where they may slow glucose absorption and bind to bile acids, contributing to effects on blood sugar and cholesterol. Studies indicate that oligosaccharides and polysaccharides obtained from seaweed can regulate intestinal metabolism and could manage inflammatory bowel disease.

4.6 Polyphenols

Marine crude drugs are emerging as potential treatments in many non-communicable conditions, including those involving the cardiovascular system; among the active compounds responsible for these activities, seaweed polyphenols appear to play a key role. Polyphenols in wakame contribute to its antioxidant and anti-inflammatory capacity.

5. Scientific Evidence by Area of Health

5.1 Cardiovascular Health / Blood Pressure

Human clinical evidence: A randomized case-control study for 8 weeks revealed that wakame (Undaria pinnatifida) intake at 5 g/day significantly decreased blood pressure and hypercholesterolemia risk in 36 older Japanese individuals with hypertension. This study, published in the Journal of Clinical Biochemistry and Nutrition, represents one of the more commonly cited human trials on wakame and blood pressure. The sample size was small (n=36), the population was specifically elderly Japanese individuals with hypertension, and generalizability is limited.

Preclinical (animal) evidence: Wakame hydrolysates with potent ACE inhibitory activity were administered to spontaneously hypertensive rats (SHR): systolic blood pressure decreased significantly after single oral administration, and in a long-term feeding experiment, 7-week-old SHR fed 1% and 0.1% wakame hydrolysates showed significantly suppressed elevation of systolic blood pressure for 7 weeks.

Lipid evidence: Rats fed seaweed-supplemented diets showed significantly lower LDL cholesterol levels than control rats. Fucoxanthin has been shown in animal studies to decrease white adipose tissue mass, decrease serum triglycerides, increase HDL cholesterol in serum, improve insulin resistance, diminish blood pressure, increase expression and serum levels of adiponectin, decrease expression of leptin, and promote β-oxidation by increasing expression of UCP-1.

Evidence strength: The human evidence for blood pressure effects is preliminary, consisting primarily of one small RCT. The lipid and anti-hypertensive data are largely animal and in vitro. Larger, well-controlled human trials are needed before definitive clinical conclusions can be drawn.

5.2 Obesity and Metabolic Health

Preclinical mechanisms: One study evaluated the effect of Undaria pinnatifida and fucoxanthin on biochemical, physiological, and inflammation markers related to obesity and on gene expression in white adipose tissue in a murine model of diet-induced obesity; the treatments improved energy expenditure, β-oxidation, and adipogenesis by upregulating PPARα, PGC1α, PPARγ, and UCP-1, and also ameliorated adipose tissue accumulation, insulin resistance, blood pressure, cholesterol, and triglyceride concentration in serum.

Human clinical trials — fucoxanthin: Investigators conducted a clinical trial of fucoxanthin supplementation in Japanese obese subjects, examining the effect of fucoxanthin (1 or 3 mg daily) in a double-blind placebo-controlled study; capsules containing fucoxanthin or placebo were administered for 4 weeks to male and female Japanese adults with a BMI of more than 25 kg/m². The results showed that fucoxanthin reduced body weight, BMI, and abdominal fat by acting on both visceral and subcutaneous fat, and the authors concluded that fucoxanthin may be able to improve a moderate overweight state in both men and women.

A separate trial published in Obesity evaluated a supplement containing fucoxanthin in combination with pomegranate seed oil. The effect of Xanthigen (containing 2.4 mg fucoxanthin and 300 mg pomegranate seed oil) was evaluated on body weight, body fat, and lipid profile in premenopausal obese women with non-alcoholic fatty liver disease (NAFLD) and women without liver disease (n=36) after 16 weeks of dosing; demonstrated results included reduced waist circumference in the NAFLD group and decreased body weight in both the NAFLD and the non-liver-disease groups.

Fucoxanthinol appears to be the most active metabolite of fucoxanthin in humans; its maximum concentration, time to maximum concentration, and half-life were reported as 44.2 nM/mL, 4.0 hours, and 7.0 hours, respectively, with 31 mg (0.52 mg/kg body weight) suggested as safe and sufficient to induce health benefits.

Evidence strength: Human evidence for anti-obesity effects is promising but limited in scope. Trials are generally small, short in duration, and some use fucoxanthin in combination with other ingredients (e.g., pomegranate seed oil), making it difficult to attribute effects to fucoxanthin alone. Larger, independent, well-controlled human trials are needed.

5.3 Blood Glucose and Diabetes

Preclinical evidence: Fucoxanthin, a characteristic carotenoid of brown algae, has been reported to exert an anti-diabetic effect in obese murine models; wakame (Undaria pinnatifida), an edible seaweed, is rich in fucoxanthin. Further preclinical analysis examined the effect of wakame extract on the cell membrane translocation of glucose transporter-4 (GLUT4) and activation of insulin signal molecules such as AKT and AMPK in insulin-sensitive tissues. Fucoxanthin has been shown to promote GLUT4 translocation in the soleus muscle and up-regulate GLUT4 expression in the EDL muscle, preventing and improving hyperglycemia through effective glucose uptake depending on the muscle types.

Human clinical evidence: A clinical trial carried out in Japan evaluated the effect of oil from Akamoku algae (Sargassum horneri) enriched with fucoxanthin at a dose of 2.0 mg/day administered for eight weeks in adults with normal and overweight status (n=20); a decrease in HbA1c was observed in the group receiving fucoxanthin, which was directly related to serum levels of fucoxanthinol, with the HbA1c decreasing predominantly in subjects carrying the G/G allele of UCP1.

Evidence strength: Anti-diabetic evidence in humans is very preliminary. Existing trials are small and some involve related (but not identical) seaweed species. Evidence is largely preclinical (animal/cell studies).

5.4 Gut Microbiota and Intestinal Health

Human clinical study: Wakame is an edible seaweed common in the Japanese diet that exhibits various biological effects and is rich in dietary fibre; despite the long history of its intake, changes in the intestinal environment following its ingestion were unclear. Investigators examined the effect of a 2-week intake of wakame on defecation frequency and the intestinal microbiota of 22 healthy individuals suffering from low defecation frequency in an open-label clinical study. These observations suggested that wakame intake improves intestinal environment and increases the faecal population of bifidobacteria, indicating that it may have prebiotic properties. Based on terminal restriction fragment length polymorphism (T-RFLP) analysis, the fraction of bifidobacteria as a percentage of all faecal bacteria increased significantly during the wakame intake period.

In vitro / mechanistic evidence: To gain a deeper understanding of the effects of fucoidan from Undaria pinnatifida on the colonic microbiome, a validated in vitro gut model was applied; following a three-week intervention period on adult faecal samples from three healthy donors, UPF supplementation had a profound butyrogenic effect while also enriching colonic microbial diversity, consistently stimulating saccharolytic genera, and reducing genera linked with potentially negative health effects in both regions of the colon. Short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, are the main metabolites of prebiotic fermentation; these metabolites have physiological functions influencing intestinal health, including regulating luminal pH, fuelling intestinal epithelial cells, improving inflammatory response, stimulating cancer cell apoptosis, and inhibiting pathogenic bacterial growth.

Wakame is increasingly recognised as a dietary prebiotic: its sulfated polysaccharide fucoidan resists upper-gut digestion and is selectively fermented by colonic microbes, enriching Bifidobacterium and Lactobacillus, increasing butyrate production, and improving host metabolic markers.

Evidence strength: The human intestinal evidence consists of one small open-label study with limited controls. In vitro fermentation models provide mechanistic support. Larger controlled human trials are needed to establish clinical relevance.

5.5 Immune Function

Immunomodulatory mechanisms: Studies in vitro and in animal models have shown that fucoidan can increase the activity of NK (Natural Killer) cells; these "sentinels" of the immune system constantly patrol to eliminate abnormal cells. A study published in Marine Drugs demonstrated that fucoidan from brown algae could increase the production of certain cytokines (IL-12, IFN-γ) involved in coordinating the immune response, and fucoidan appears to help the immune system communicate in a more coordinated manner.

Antiviral potential: Mekabu fucoidan showed potential antiviral activities against herpes simplex viruses, human cytomegalovirus, and influenza A virus. A clinical trial in elderly participants found that those who consumed mekabu fucoidan for 24 weeks before receiving an influenza vaccination produced significantly more neutralising antibodies, particularly against influenza B virus, compared to controls.

Evidence strength: Immune-modulating effects of mekabu/wakame fucoidan are supported by in vitro and animal data, and by at least one clinical trial in elderly subjects related to vaccination response. More rigorously designed human trials are needed, including in non-elderly populations and against a wider range of clinical endpoints.

5.6 Oncology / Cancer

Preclinical evidence: The anticancer activity of fucoidan extracted from Undaria pinnatifida was investigated in human hepatocellular carcinoma SMMC-7721 cells; SMMC-7721 cells exposed to fucoidan displayed growth inhibition and several typical features of apoptotic cells, such as chromatin condensation and marginalization, a decrease in the number of mitochondria, and mitochondrial swelling and vacuolation.

Researchers cultivated high-fucoxanthin wakame and investigated its effect on an AOM/DSS carcinogenesis mouse model; fucoxanthin-high wakame at 30 mg/kg body weight significantly decreased the number of cells composing the tumour microenvironment, including colorectal cancer stem cell-like CD44^high/EpCAM^high cells (reduced 0.6-fold), cancer-associated fibroblast-like αSMA^high cells (reduced 0.5-fold), and tumour-associated macrophage-like CD206^high cells (reduced 0.5-fold), while apoptotic cleaved caspase-3^high cells increased 1.7-fold.

Evidence strength: Anti-cancer evidence for wakame and its constituents is primarily in vitro (cell culture) and in animal models. There are no published human clinical trials demonstrating therapeutic anti-cancer effects of wakame consumption. This area remains exploratory.

5.7 Iodine Bioavailability and Thyroid Nutrition

A randomized crossover trial assessed whether iodine from a meal consisting of sushi with nori (Porphyra spp.) and a wakame seaweed salad (Undaria pinnatifida) had similar bioavailability to a potassium iodide reference supplement of similar iodine content; 20 healthy young women were studied, with one intervention arm consuming a meal containing approximately 231 μg iodine and the other consuming a potassium iodide supplement containing 225 μg iodine, and urinary iodine concentration was measured at 11 time points over 48 hours.

Seaweed consumption was associated with increased urinary iodine and total arsenic concentrations, particularly after kombu and wakame consumption. Before wakame consumption, the mean urinary iodine concentration was 134 (SD 131) μg/L, which increased to 314 (SD 120) μg/L after three days of consumption.

The iodine content of seaweeds is highly variable depending on factors such as species, area of the plant, stage of growth, season, and geographical location. In general, the iodine content of brown seaweeds is greater than that of red or green seaweeds.

Evidence strength: Wakame's iodine content is established, and its bioavailability from food (as iodine in bioavailable form) is supported by crossover trial data. Whether this iodine translates to meaningful thyroid benefit in iodine-sufficient populations is not clearly demonstrated in clinical trials.

5.8 Bone Health

Laboratory evidence catalogues antiosteoporotic properties among wakame's activities. The mineral composition of wakame, notably its calcium content, provides a theoretical basis for bone health applications. However, specific human clinical trials examining bone density or fracture outcomes with wakame consumption had not been identified in available peer-reviewed sources at the time of this article's preparation. Evidence in this area remains preliminary and preclinical.

6. Dosage Forms and Reported Dosages

Dosages below are reported as used in published studies only, not as recommendations:

Whole dried wakame (food/dietary supplement): A randomized case-control study used an intake of 5 g/day of wakame for 8 weeks in hypertensive subjects.
Fucoxanthin (isolated or enriched extract):
- A double-blind placebo-controlled study used fucoxanthin at 1 mg or 3 mg daily, administered in capsules for 4 weeks to adults with BMI greater than 25 kg/m².
- A supplement containing 2.4 mg fucoxanthin and 300 mg pomegranate seed oil was evaluated over 16 weeks in premenopausal obese women.
- A dose of 31 mg (0.52 mg/kg body weight) was identified in pharmacokinetic analysis as safe and sufficient to induce health benefits.
- Clinical trials use 2.4–12 mg of purified fucoxanthin extract daily; fresh wakame contains roughly 0.73 mg/g dry weight.
Mekabu fucoidan (clinical context): A clinical trial used mekabu fucoidan for 24 weeks before influenza vaccination in elderly participants. Specific per-day dosages from that trial were not reported in available source material.
Wakame for intestinal health: An open-label study examined the effect of a 2-week intake of wakame in 22 healthy individuals with low defecation frequency. Specific gram quantities were not disclosed in available source material.

7. Safety Considerations and Notable Interactions

7.1 Iodine Excess and Thyroid Function

While seaweed could be useful in tackling dietary iodine insufficiency, consumption of some species and sources of seaweed has also been associated with risks such as toxicity from high iodine levels, or accumulation of arsenic, heavy metals, and contaminants. All seaweeds have the ability to concentrate iodine from seawater, and the iodine content of seaweeds is highly variable depending on factors such as species, area of the plant, stage of growth, season, and geographical location.

Population groups vulnerable to high iodine intakes should avoid consuming macroalgae in order to reduce the risk of negative health consequences of excessive iodine intakes. Excess iodine from kelp supplements can alter the dosage requirements for levothyroxine, a thyroid hormone replacement medication, in ways that are not predictable.

Among seaweed-containing products evaluated in a UK survey, the median iodine content was 110 μg/g, and 26 products could potentially lead to an iodine intake above the (European) tolerable adult upper level of 600 μg/day.

7.2 Heavy Metal and Arsenic Accumulation

Chemical composition analyses of algae showed differences between species and the presence of heavy metals; arsenic, cadmium, and aluminium were confirmed in seaweed samples, with all samples containing arsenic ranging from 6.65 to 76.48 mg/kg. Seaweed consumption has been associated with increased urinary total arsenic concentrations, particularly after kombu and wakame consumption. Seaweeds can also entrap heavy metals including aluminium, cadmium, iron, and particularly arsenic.

Among the contaminants assessed by the European Food Safety Authority (EFSA), the highest mean occurrence levels were reported for iodine; among heavy metals, the highest mean was for arsenic; mean concentrations of mercury in seaweeds were the lowest; a relatively high variation in heavy metals and iodine levels was found across seaweed samples even within species; overall, the highest mean levels were reported for brown seaweeds, followed by red and green seaweeds.

7.3 Anticoagulant Interactions

Fucoidan from the sporophyll (mekabu) of Undaria pinnatifida possesses anticoagulant biological activity. Wakame is catalogued as displaying anticoagulant properties in laboratory evidence. Given this intrinsic anticoagulant activity, high-dose fucoidan or wakame supplementation could theoretically interact with anticoagulant medications such as warfarin or direct oral anticoagulants, though specific clinical pharmacokinetic interaction studies in humans were not identified in available sources.

7.4 Sodium Content

Eating 5 g per day or more of dried seaweed can create a situation where sodium intake becomes excessively high. This is relevant for individuals managing hypertension or cardiovascular disease, as salted and dried wakame products may contribute meaningfully to daily sodium load.

7.5 Tolerability of Fucoxanthin

In most studies, fucoxanthin has been well-tolerated with few reported adverse effects; some participants in clinical trials reported mild digestive issues such as bloating or diarrhoea, especially at higher doses, and these symptoms were usually temporary and subsided as the body adjusted.

7.6 Pregnancy and Lactation

In Korea, miyeok-guk soup is consumed by women after giving birth as sea mustard (miyeok) contains high content of calcium and iodine, nutrients important for new nursing mothers, and many women consume it during the pregnancy phase as well. However, pregnant women should monitor iodine intake to avoid overconsumption.

8. Body Systems and Health Areas Associated with Wakame

Cardiovascular system: ACE-inhibitory peptides, blood pressure modulation, cholesterol effects, and anti-inflammatory activity of fucoidan and fucoxanthin.
Endocrine / Thyroid: Iodine supply relevant to thyroid hormone synthesis; risk of dysfunction at excessive intake.
Metabolic / Adipose tissue: UCP1-mediated thermogenesis, anti-obesity, insulin sensitisation, and glucose transporter activity mediated by fucoxanthin.
Gastrointestinal / Gut microbiota: Prebiotic effects of fucoidan and alginate; enrichment of Bifidobacterium and Lactobacillus; increased SCFA production.
Immune system: NK cell activation, cytokine modulation (Th1/Th2 balance), and antiviral properties of mekabu fucoidan.
Oncology (preclinical): Apoptosis induction in cancer cell lines, tumour microenvironment modulation (animal models only).
Skeletal / Bone: High calcium and vitamin K content; antiosteoporotic activity documented preclinically.
Coagulation: Anticoagulant activity of fucoidan.

References

Health Conditions

Health conditions that Wakame may help support.

No conditions available.

Body Systems

Body systems that Wakame may help support.

No body systems available.